1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA

FME.SW
Fresenius Medical Care AG & Co. KGaACH flagSwiss Exchange
32.99
CHF
- -
- -
9.68BMarket Cap
Fresenius Medical Care AG & Co. KGaA
FME.SW
(Swiss Exchange)

Recent

price

32.99

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
29.87
32.44
- -
- -
- -
- -
- -
- -
- -
- -
- -
60.14
66.15
66.3
65.9
67.4
67.53
Revenue per Share
2.47
2.76
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.31
2.3
1.7
1.83
3.36
3.3
Basic EPS, GAAP
2.13
2.19
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.58
4.92
6.63
5.75
6.06
6.23
Free Cash Flow per Basic Share
0.59
0.72
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.34
1.35
1.12
1.19
1.45
- -
Dividend per Share
9.73
12.95
- -
- -
- -
- -
- -
- -
- -
- -
- -
37.96
37.53
38.22
39.4
42.93
43.94
Book Value per Share
-3.31
-4.69
- -
- -
- -
- -
- -
- -
- -
- -
- -
-6.29
-6.35
-4.04
-2.63
-1.87
-3.13
Tangible Book Value per Share
298
299
- -
- -
- -
- -
- -
- -
- -
- -
- -
293
293
293
293
291
287
Basic Weighted Avg Shares
8,906
9,699
10,435
10,580
13,019
15,455
16,570
17,784
16,547
17,477
17,859
17,619
19,398
19,454
19,336
19,628
19,358
Sales/Revenue/Turnover
16.17
16.22
15.69
15.26
14.08
13.59
14.1
12.76
13.03
12.56
12.37
10.55
7.5
7.59
7.59
9.31
9.41
Operating Margin (%)
378
430
456
469
575
648
702
735
790
1,593
1,786
1,624
1,838
1,752
1,742
1,500
1,569
Depreciation Expense
736
826
897
804
860
955
1,144
1,280
1,982
1,200
1,164
969
673
499
538
978
945
Net Income, GAAP
35.18
33.8
31.32
32.04
31.66
31.82
30.58
22.18
18.67
21.83
25.85
22.45
26.65
29.1
29.9
21.22
20.6
Effective Tax Rate (%)
8.26
8.52
8.6
7.6
6.6
6.18
6.9
7.2
11.98
6.86
6.52
5.5
3.47
2.57
2.78
4.98
4.88
Profit Margin (%)
1,025
1,105
2,236
1,979
2,665
2,395
1,585
1,074
1,579
106
1,219
710
1,736
2,590
2,263
1,653
1,378
Working Capital
3,240
4,240
5,930
5,610
7,413
7,183
6,833
5,795
5,046
10,525
10,683
10,735
11,176
10,489
9,761
8,598
8,641
LT Debt
5,657
6,219
6,962
6,869
8,247
9,600
11,051
10,828
12,902
13,227
12,331
13,979
15,449
14,827
15,769
14,283
14,205
Total Equity
10.61
9.8
8.92
8.24
8.53
8.45
8.75
9.36
9.03
7.19
6.28
5.49
3.78
3.73
3.79
5.49
5.57
Return on Invested Capital (%)
12.95
11.22
10.09
8.3
7.51
6.64
7.36
8.44
12.47
6.31
4.9
3.99
2.79
2.26
2.57
4.45
4.25
Return on Capital (%)
29.01
24.4
21.46
17.13
15.55
13.93
16.41
18.5
23.9
12.69
11.47
8.95
6.09
4.49
4.72
8.13
7.76
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,137
2,197
2,389
LT Borrowings
6,323
5,692
5,741
LT Finance Leases
3,012
2,906
2,899
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
290
279
270
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
7,824
7,898
8,108
Cash, Cash Equivalents & STI
1,813
1,821
1,623
Accounts Receivable, Net
3,242
3,161
3,582
Inventories
2,086
2,141
2,303
Total Current Liabilities
5,759
6,245
6,730
Payables & Accruals
1,000
1,378
1,042
ST Debt
1,137
2,197
2,389
Deferred Revenue
- -
114
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.48%
3.36%
-9.42%
Free Cash Flow
14.54%
-6.84%
4.67%
Net Income, GAAP
6.06%
3.3%
81.88%
Sales/Revenue/Turnover
2.53%
1.99%
1.51%
Total Cash Common Dividend
6.51%
4.58%
21.01%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,725
4,766
4,760
5,085
19,336
2025
4,881
4,792
4,885
5,070
19,628
2026
4,612
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
0.64
0.73
0.23
1.83
2025
0.52
0.77
0.94
1.14
3.36
2026
0.43
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.19
2025
- -
- -
- -
- -
1.45
2026
- -
- -
- -
- -
- -
Similar Companies
Surgery Partners, Inc. (SGRY)
ATI Physical Therapy, Inc. (ATIP)
Ramsay Health Care Limited (RHC.AX)
Nexteligent Holdings, Inc. (NXGT)
Kindred Healthcare, Inc. (KND)
IMAC Holdings, Inc. (IMACW)
Business
Fresenius Medical Care AG & Co. KGaA is the world's leading provider of products and services for individuals with chronic kidney disease and end-stage renal disease, operating a global network of approximately 3,700 dialysis clinics that served more than 299,000 patients as of December 31, 2024. The company offers dialysis products including machines, dialyzers, water treatment systems such as reverse osmosis units, and related disposables; renal pharmaceuticals for treating anemia, mineral bone disorders, and other kidney disease complications; acute care services encompassing continuous renal replacement therapy for acute kidney injury; vascular access management for arteriovenous fistulas and grafts; and home-based hemodialysis and peritoneal dialysis solutions. It maintains around 40 production sites across all continents and conducts worldwide research and development to advance renal therapies and technologies. Fresenius Medical Care AG & Co. KGaA serves dialysis clinics, hospitals, intensive care units, vascular surgeons, and patients requiring in-center or at-home treatments, with a focus on value-based care delivery in North America and other regions. Founded in 1996 through the merger of Fresenius AG and National Medical Care, the company is headquartered in Bad Homburg v. d. Höhe, Germany, with significant U.S. operations including a major facility in Waltham, Massachusetts. It operates as a separately listed entity following strategic initiatives by parent Fresenius SE & Co. KGaA to deconsolidate it into an AG legal form, enhancing governance flexibility and focus on kidney care. Among recent developments, Fresenius Medical Care reported accelerated revenue growth in the third quarter of 2025, building on momentum from value-based care expansions in 2024 and 2023. The company initiated a share buyback program in June 2025, while its parent Fresenius SE plans corresponding share sales to optimize capital structure. Additionally, Fresenius received a €400 million loan from the European Investment Bank in September 2025 to support R&D, innovation, and manufacturing capacity expansion for medical products and biosimilars in Europe.